Biotech Values

[biocqr]

IDRA: How significant is it that the MOA of IMO-3100 involves the IL-17 pathway?

DNA microarray (available on biopsies from a subset of pts) showed IMO-3100 treated pts had significant improvement in the expression profiles of MAD-3 psoriasis genes and IL-17 related genes.

Biopsy samples from six pts treated with the .16 mg/kg and six with the placebo were analyzed by DNA microarray fro expression of the MAD-3 gene set (related to the pathogenesis of proiasis and genes unique to the IL-17 pathway, a critical mechanism of immunopathology.

The pts treated with IMO-3100 showed significant improvement compared to placebo in expression profile of both disease associated MAD-3 genes and the IL-17 pathway genes (each p<10-6)

https://docs.google.com/viewer?url=http%3A%2F%2Fwww.iderapharma.com%2Fdevelopment%2FIID_Poster_2013.pdf

Meta-Analysis Derived (MAD) Transcriptome of Psoriasis Defines the “Core” Pathogenesis of Disease
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0044274

Novartis grabs lead IL-17 program as Ensemble adds another marquee deal

Last month Novartis boasted that it's anti-IL-17 treatment, secukinumab, beat out Enbrel in a head-to-head psoriasis study. This new deal with Ensemble offers a complementary oral companion to an injectable Novartis recently tapped as one of 14 leading drug hopefuls in the late-stage pipeline. In addition to psoriasis, Novartis plans to release more late-stage results on secukinumab for arthritic conditions next year. And the pharma giant told investors two years ago that secukinumab was a blockbuster contender, with its first regulatory filing slated for later this year.

http://www.fiercebiotech.com/story/novartis-grabs-lead-il-17-program-ensemble-adds-another-marquee-deal/2013-08-06#ixzz2d57BVJai